Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Allergan

Teva Pharmaceutical Industries Inc and AbbVie's Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced.

San Francisco reaches $54 million opioid settlement with Teva and Allergan

New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Teva and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Teva Pharmaceutical Industries Limited - TEVA

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Dr. Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as

Teva Announces Appointment of New Global R&D and Chief Medical Officer

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will

Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022

Amazon

2 Buffett Stocks That Outperformed the S&P During the Great Recession

AMSTERDAM--(BUSINESS WIRE)--Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Eu

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)

The Health Care sector has been relatively strong this year amid stock market volatility. Teva Pharmaceuticals struggles with opioid lawsuits, generic drug issues as shares drift lower.

Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week

Ford Motor Company

Western Digital

These highly profitable stocks are valued at just three to six times Wall Street's forecast earnings for 2023.

Nasdaq Bear Market: 3 of the Cheapest Stocks You Can Confidently Buy Right Now

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo to resolve the dispute over Aurobindo's Abbreviated New Drug Application (“ANDA") for a generic deutetrabenazine product. Teva and Aurobindo have been involved in a patent infringement litigation in which Teva asserted a number of patents ag

Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that eight abstracts examining real-world data to better understand the use of AJOVY® (fremanezumab-vfrm) injection in patients with migraine will be presented at the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado. The data presented at this year's AHS meeting will focus on real-w

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting

SANTA BARBARA, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals today launched a new program to expand medication access and provide grant funding to free and charitable clinics that care for medically underserved patients suffering from depression and/or anxiety. Teva is providing free and charitable clinics with $2 million in grant funding over two years and making available, on a charitable bas

Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services

If we look at stock returns, Abbott's -1% return is better than Teva's -13% change over the last twelve months.

Here's A Better Pick Over Abbott Stock

(Reuters) -Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday.

Teva, Allergan reach $161.5 million opioid settlement with West Virginia

Teva Pharmaceutical Industries Ltd. TEVA, +1.95% said Wednesday it agreed to make $110 million in payments to settle opioid claims against it by West Virginia.

Teva Pharmaceutical to pay $110 mln to settle opioid charges in W. Va.

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of West Virginia that settles the state's and its subdivisions opioid-related claims. The settlement will provide West Virginia with $75 million over 15 years in addition to $8 million in attorneys' fees and costs incurred during the trial. Teva will also provide its life-s

Teva Reaches Agreement With West Virginia to Settle the State's Opioid-Related Claims

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new efficacy and safety data from a 3-year open-label extension (OLE) study on AUSTEDO® (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia (TD). These data will be presented at the 2022 American Psychiatric Association (APA) Annual Meeting, held May 21-25 in New Orleans and online June 7-10. In addition

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder. ProAir Digihaler is a breath-actuated,.

Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients

Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA) stock, according to BofA Securities.

BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal

AMSTERDAM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia® for the treatment of neovascular (wet) age-related macular degeneration (“AMD”). Ongavia® is also licenced for: the treatment of visual impairment due to diabetic macular oe

United Kingdom first to grant licence for Teva's ophthalmology biosimilar Ongavia (ranibizumab)▼

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four data presentations for AUSTEDO® (deutetrabenazine) tablets and TV-46000/mdc-IRM. These data will be presented at the American Psychiatric Association (APA) Annual Meeting held May 21-25, 2022 in New Orleans, Louisiana, and again virtually June 7-10, 2022. Featured data at this year's APA Annual Meeting include findings fr

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new study findings based on newly established clinical thresholds on short-acting beta agonist (SABA) use that highlight real-world SABA usage among patients with asthma in the U.S. and the potential for ProAir® Digihaler® (albuterol sulfate) inhalation powder, a digital inhaler, to help inform treatment discussions and decisions. T

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges

MONTRÉAL--(BUSINESS WIRE)--Public formulary and program coverage makes AJOVY® (fremanezumab) accessible to more migraine patients across Canada

Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada's AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in Adults

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new findings will be presented at the 2022 American Thoracic Society (ATS) 2022 Annual Meeting that apply clinical thresholds for short-acting beta agonist (SABA) use established by independent expert consensus to objective patient data from ProAir Digihaler (albuterol sulfate) Inhalation Powder. These findings are t

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting

AT&T

Weightwatchers International Inc.

With the broader market tumbling, value stocks are bound to come into focus.

Stock Market Plunge: 2 Value Stocks to Buy and 1 to Avoid Like the Plague

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a leading global pharmaceutical company providing medicines to nearly 200 million people daily, published its 2021 ESG Progress Report today. The report details how Teva further integrated ESG into its business strategy—implementing a strengthened ESG governance structure and setting 13 ambitious targets related to access to medicines, ethics, environment and responsible supply chain, some of which are

News for Teva Pharmaceutical Stock (TEVA)